HUTCHMED (China) Ltd Files Routine 6-K Report
Ticker: HMDCF · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1648257
| Field | Detail |
|---|---|
| Company | Hutchmed (China) LTD (HMDCF) |
| Form Type | 6-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, 6-K, foreign-private-issuer
TL;DR
HUTCHMED filed a 6-K, just routine reporting, no big news.
AI Summary
HUTCHMED (China) Limited filed a Form 6-K on September 24, 2024. This filing is a report of a foreign private issuer and does not contain specific financial updates or material events beyond its routine reporting status. The company is incorporated in E9 and its principal executive offices are located in Hong Kong.
Why It Matters
This filing indicates HUTCHMED is meeting its reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a standard, routine filing by a foreign private issuer and does not contain new material information that would typically impact risk.
Key Players & Entities
- HUTCHMED (China) Limited (company) — Filer of the report
- 001-37710 (company) — Commission File Number
- 20240924 (date) — Filing date
FAQ
What type of filing is HUTCHMED (China) Limited submitting?
HUTCHMED (China) Limited is submitting a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on September 24, 2024.
Where are HUTCHMED's principal executive offices located?
HUTCHMED's principal executive offices are located at 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Does HUTCHMED file annual reports under Form 20-F or 40-F?
The filing indicates that HUTCHMED files annual reports under cover of Form 20-F.
What is the SIC code for HUTCHMED (China) Ltd?
The Standard Industrial Classification (SIC) code for HUTCHMED (China) Ltd is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 165 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-09-24 06:09:13
Filing Documents
- hcm-20240924x6k.htm (6-K) — 20KB
- hcm-20240924xex99d1.htm (EX-99.1) — 50KB
- hcm-20240924xex99d1001.gif (GRAPHIC) — 4KB
- 0001648257-24-000076.txt ( ) — 76KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-37710 HUTCHMED (CHINA) LIMITED (Translation of registrant's name into English) 48th Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F HUTCHMED (CHINA) LIMITED Form 6-K EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 Announcement relating to HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. HUTCHMED (CHINA) LIMITED By: /s/ Johnny Cheng Name: Johnny Cheng Title: Chief Financial Officer Date: September 24, 2024 3